Bayer Wins Latest Philadelphia Trial Over Weedkiller Roundup
By Sabela Ojea
Bayer said it won a trial over its Roundup weedkiller product liability trial in Philadelphia.
The German pharmaceutical and agricultural conglomerate on Tuesday said it won the case before Judge Ann Butchart.
"While we have great sympathy for anyone who suffers a loss or injury, science proves that Roundup is not carcinogenic," Bayer said.
The company has, however, been ordered to pay billions of dollars in damages over the past few years in cases that alleged Roundup caused cancer.
Bayer maintains that Roundup and its main ingredient, glyphosate, is safe to use and has cited reviews by the U.S. Environmental Protection Agency and other regulators that have determined it doesn't pose a cancer risk. The European Union said in recent days that it would extend glyphosate's use for 10 more years.
Bayer lost the first trial over Roundup's alleged cancer risk in August 2018, shortly after the company completed its $63 billion acquisition of Monsanto, which developed Roundup as well as genetically engineered crops designed to withstand the herbicide.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
March 05, 2024 19:04 ET (00:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
The 10 Best Dividend Stocks
-
The Most Attractive Investment Opportunities in Oil & Gas
-
Apple: Generative AI Strategy Should Drive Sales and Upgrades
-
2 Undervalued Stocks That Just Raised Dividends
-
2 Popular Stocks That Top Managers Are Selling
-
The Best REITs to Buy
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy